TERRI TEBO: Open Payments
NPI 1881876092 · BREMEN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 47 payments from 7 companies in 2025. Trend: 2023 $200 · 2024 $617 · 2025 $882
Food & beverage: $882
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $174 |
| Teva Pharmaceuticals USA, Inc. | 14 | $159 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| ABBVIE INC. | 4 | $75 |
| Janssen Pharmaceuticals, Inc | 2 | $57 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
Products named: INGREZZA, CAPLYTA, AUSTEDO XR, VRAYLAR, INVEGA SUSTENNA, ABILIFY MAINTENA, COBENFY, UZEDY.
Industry payments across GA — which companies pay providers there.
